Evaluation of a Blood-Based Cepheid 3-Gene Host Response Assay for Tuberculosis Diagnosis in a Specialized Respiratory Hospital in China - Takeaways - MDSpire

Evaluation of a Blood-Based Cepheid 3-Gene Host Response Assay for Tuberculosis Diagnosis in a Specialized Respiratory Hospital in China

  • By

  • Miaomiao Zhao

  • Yanyang Zhou

  • Hui Chen

  • Lina Huang

  • Tingting Chen

  • Lulu Xu

  • Ping Xu

  • February 4, 2026

  • 0 min

Share

  • 1

    Tuberculosis remains a significant global health threat, with 10.8 million new cases and 1.25 million deaths reported in 2023.

  • 2

    China ranks third globally in TB burden, with an estimated 741,000 new cases in 2023, highlighting the need for improved diagnostic methods.

  • 3

    The Cepheid Xpert MTB-HR assay utilizes a blood-based approach to diagnose pulmonary TB, enhancing test stability and reproducibility.

  • 4

    This study evaluates the diagnostic efficiency of the Xpert MTB-HR assay in a specialized respiratory hospital in China.

  • 5

    The study aims to address the limitations of current TB diagnostics by providing a rapid, non-sputum-based testing option.

Original Source(s)

Evaluation of a Blood-Based Cepheid 3-Gene Host Response Assay for Tuberculosis Diagnosis in a Specialized Respiratory Hospital in China

  • by Miaomiao Zhao, Yanyang Zhou, Hui Chen, Lina Huang, Tingting Chen, Lulu Xu, Ping Xu

  • February 4, 2026

Related Content

SARS-CoV-2 in Pregnancy—More Hints of Rare Complications

A device-invariant multi-modal learning framework for respiratory disease classification

Ebola at the World Cup? Here’s what we should actually worry about